Donanemab detects a minor fraction of amyloid-β plaques in post-mortem brain tissue of patients with Alzheimer's disease and Down syndrome.

Acta Neuropathol · 2022 · PMC9038931 · PMID 35429251

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significancep = 0.09so close (0.05 < p ≤ 0.1)

The pan-AβpE3 positive plaques accounted for 49%, and for donanemab, only 34% (lower donanemab-positive plaque load versus pan-AβpE3 did not reach statistical significance; t test, p = 0.09).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.